Since healthcare benefit costs continue to rise, large employers are increasing efforts to stem the increases, according to the annual survey by the National Business Group on Health.
Since healthcare benefit costs continue to rise, large employers are increasing efforts to stem the increases, according to the annual survey by the National Business Group on Health.
Based on the survey results, employers are beginning to implement new initiatives in 2020 for more virtual care solutions (51%) and new strategies on high cost claims (39%). According to the 2020 Large Employers' Health Care Strategy and Plan Design Survey, health benefits are expected to rise 5% in 2020—with cost management initiatives considered.
“One of the challenges employers face in managing their health care costs is that health care is delivered locally and change is not scalable. It’s a market-by-market effort,” Brian Marcotte, president and chief executive officer of the National Business Group on Health, said in a statement. “Employers are turning to market-specific solutions to drive meaningful changes in the health care delivery system.”
Additionally, the survey revealed that 44% of employers ranked musculoskeletal issues as the top condition that impacts their costs and 85% ranked it among the top 3 conditions. However, the research noted that 25% of employers ranked cancer as the top condition.
“Virtual care solutions bring health care to the consumer rather than the consumer to health care. They continue to gain momentum as employers seek different ways to deliver cost effective, quality health care while improving access and the consumer experience,” Marcotte added. “Of particular note is the growing interest among employers to offer virtual care for mental health as well as musculoskeletal conditions.”
Among priorities in the future, virtual care and pharmacy benefits cost management were emphasized in the study. For 2020, 64% of employers believe virtual care will play a significant role in health care delivery while 85% of respondents rated high-cost drugs as the number one or two most concerning pharmacy issue.
The study also noted that most employers are hesitant about Medicare for All. Although 72% of employers believe that it will reduce the number of uninsured, 81% believe it will increase taxes. Also, 57% said it would lead to higher health costs and 47% said it would lead to higher employee costs.
Insurance Coverage Limits JAKi Therapy Access for Patients With AA, Especially Non-White Populations
April 25th 2024A survey study showed major barriers to Janus kinase inhibitor (JAKi) therapy for patients with alopecia areata, especially for non-White patients who face higher rates of being uninsured and struggle more to afford the treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More